DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2009/0004173 A1 Evans Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

US 200900.041.73A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0004173 A1 Evans et al. (43) Pub. Date: Jan. 1, 2009 (54) DIAGNOSIS AND TREATMENT OF DRUG Related U.S. Application Data RESISTANT LEUKEMA (60) Provisional application No. 60/575,762, filed on May 28, 2004. (75) Inventors: William E. Evans, Cordova, TN Publication Classification (US); Robert Pieters, Rotterdam (51) Int. Cl. (NL); Meyling H. Cheok, A638/50 (2006.01) Memphis, TN (US); Monique L. GOIN 33/50 (2006.01) den Boer, Rotterdam (NL); C40B 30/06 (2006.01) Wenjian Yang, Germantown, TN A63L/437 (2006.01) (US) C40B 40/00 (2006.01) A6IP35/02 (2006.01) A63L/35 (2006.01) Correspondence Address: A 6LX 3/573 (2006.01) ALSTON AND BIRD LLP C40B 30/00 (2006.01) ST. JUDE CHILDREN'S RESEARCH HOSP (52) U.S. Cl. ................ 424/94.6; 702/19; 506/10; 506/7; TAL 514/285; 514/459; 506/13 BANK OF AMERICA PLAZA, 101 SOUTH TRYON STREET, SUITE 4000 (57) ABSTRACT CHARLOTTE, NC 28280-4000 (US) The present invention encompasses methods and composi tions useful in the diagnosis and treatment of drug resistant (73) Assignee: St. Jude Children's Research leukemia. The invention provides a number of genes that are Hospital, Memphis, TN (US) differentially expressed between drug resistant and drug sen sitive acute lymphoblastic leukemia (ALL). These genes act as biomarkers for drug resistant leukemia, and further serve as (21) Appl. No.: 11/597,468 molecular targets for drugs useful in treating drug resistant leukemia. Accordingly, the invention provides methods of diagnosing drug resistant leukemia and methods of selecting (22) PCT Filed: May 18, 2005 a therapy for Subjects affected by drug-resistant leukemia. The invention also provides methods for Screening for com (86). PCT No.: PCT/US2OOS/O17424 pounds for treating drug-resistant leukemia, and improved methods for treating drug-resistant leukemia. Compositions S371 (c)(1), of the invention include arrays, computer readable media, and (2), (4) Date: Aug. 12, 2008 kits for use in the methods of the invention. 3 Š s a Sensitive - - - - - -H-H-H - - - - - - - - - - - - - - - - - - termediate s 8 Resistant 9 : s s d is s s0.001 - No. atris' 2 * Years 6 8 10 Sensitive 5 5s 52 46 4. s s 3. interediate s2 8 35 8 8 3. Resistant 52 42 29 2 s 3. 2 b St.o wawaii. wr w w w w w w w 48 x w w w w w w x w---- a r + · ·sis r- 4 4-war a s 3 T. Ti----------------HoSersitive s intermediate 8 Resistant i ro is N PO.003 - to a Risk" 2 4 Years 6 8 10 Sense 28 2 26 2. 2S 9 $3. 9 4 Interediate 4S 44 43 3s 2 23 i8 Resistant 7 18 15 s 2 f s s s3 Patent Application Publication Jan. 1, 2009 US 2009/0004173 A1 a 3 ... -----------H----------. ---- . .--...-H... Sensitive intermediate Resistant O No. at Risk 2 4. Years 6 8 10 Sensitive S9 5S 52 46 27 4. 5 5 3. lintermediate 52 46 35 28 9. S 4. 3. Resistant 52 42 29 20 18 12 5 3. 2 O we5 ...t------. 4. For - or ss a s r s a r as a a e a a a a a e --- a r s as a ---- - - - - - - - - - - - - - - s O !----------- Sensitive N- do ------H-H----------H--- g intermediate o o Resistant 8 C. b v i S. O C P=0.003 No. at Risk 2 4 Years 6 8 10 Sensive 28 2 25 26 2S 25 19 3. s 4 interediate 45 44 43 39 35 29 23 8 Resistant 17 16 15 ts 12 2 f 5 5. s 13 F.G. 1 US 2009/00041 73 A1 Jan. 1, 2009 DAGNOSIS AND TREATMENT OF DRUG 0007. The subject expression profile and the reference RESISTANT LEUKEMA expression profile comprise values representing the expres sion levels of genes that are differentially expressed in drug FEDERALLY SPONSORED RESEARCHOR resistant versus drug-sensitive leukemia. In particular DEVELOPMENT embodiments, the profiles comprise values representing the 0001. This invention was made in part with U.S. Govern expression levels of genes selected from the genes shown in ment Support under National Institutes of Health grant nos. Tables 6A, 6B, 6C, 6D, 7A, 7B, 7C, 7D, 8A, 8B, 8C, 8D,9A, R37 CA36401, R01 CA78224, RO1 CA51001, RO1 9B, 9C, 9D, 10A, 10B, 11A, 11B, 12A, 12B, 13A, and 13B. CA71907, UO1 GM61393, UO1 GM61394, and Cancer Cen 0008 Tables 6A, 6B, 6C, 6D, 10A, and 10B provide genes ter Support Grant CA21765. The U.S. Government may have that are differentially expressed in prednisolone-resistant certain rights in this invention. ALL. Tables 7A, 7B, 7C, 7D, 11A, and 11B provide genes that are differentially expressed in Vincristine-resistant ALL. FIELD OF THE INVENTION Tables 8A, 8B, 8C, 8D, 12A, and 12B provide genes that are 0002 The present invention relates generally to genes differentially expressed in L-asparaginase-resistant ALL. associated with resistance to drugs used to treat leukemia and Tables 9A, 9B, 9C, 9D, 13A, and 13B provide genes that are methods for using these genes to improve treatment of leu differentially expressed in daunorubicin-resistant ALL. The kemia. invention also provides a method of determining the progno sis for a patient with leukemia or predicting whethera Subject BACKGROUND OF THE INVENTION affected by leukemia has an increased risk of relapse. The 0003. The treatment of pediatric acute lymphoblastic leu method comprises the steps of providing a Subject expression kemia has improved remarkably over the past four decades, profile of a sample from the subject affected by leukemia, resulting in long-term disease-free Survival of approximately providing a reference expression profile associated with 80 percent (Pui and Evans (1998) N. Engl. J. Med. 339:605 resistance to an antileukemic agent, and determining whether 615 and Pui et al. (2001) Lancet Oncol. 2:597-607. Despite the subject expression profile shares sufficient similarity to this progress, the number of patients with acute lymphoblas the reference expression profile associated with resistance to tic leukemia who are not cured with contemporary therapy the antileukemic agent. The subject affected by leukemia is exceeds the total number of children with newly diagnosed predicted to have an increased risk of relapse if the subject acute myeloid leukemia and most other childhood cancers. expression profile shares sufficient similarity to the reference Patients whose leukemia cells exhibit in vitro resistance to expression profile associated with resistance to the antileuke antileukemic agents have a significantly worse prognosis than mic agent. patients whose acute lymphoblastic leukemia cells are drug 0009. In another embodiment, the invention provides a sensitive (den Boer et al. (2003).J. Clin. Oncol. 21:3262-68; method of selecting a therapy for a subject affected by leuke Kaspers et al. (1997) Blood 90:2723-29; et al. Pieters R. mia. The method comprises the steps of providing a subject (1991) Lancet 338:399-403). expression profile of a sample from the subject affected by 0004 Little is known about the genomic determinants of leukemia, providing a reference expression profile associated leukemia cell resistance to chemotherapy. Such knowledge with resistance to at least one antileukemic agent selected would provide important new insights for overcoming drug from prednisolone, Vincristine, L-asparaginase, and dauno resistance in acute lymphoblastic leukemia. Accordingly, rubicin, and determining whether the Subject expression pro there remains a need for the identification of genes whose file shares sufficient similarity to the reference expression expression is associated with drug resistance in leukemia. profile associated with resistance to the antileukemic agent; where the therapy selected for the subject does not comprise SUMMARY OF THE INVENTION the antileukemic agent if the Subject expression profile shares 0005. The present invention encompasses methods and sufficient similarity to the reference expression profile asso compositions useful in the diagnosis and treatment of drug ciated with resistance to the antileukemic agent. resistant leukemia. The invention provides a number of genes 0010. In a further aspect, the invention provides a method that are differentially expressed between drug resistant and for screening a library of compounds to identify a compound drug sensitive acute lymphoblastic leukemia (ALL). These to improve treatment of drug resistant leukemia. The method genes act as biomarkers for drug resistant leukemia, and comprises the steps of providing a reference expression pro further serve as molecular targets for drugs useful in treating file comprising one or more values representing the expres drug resistant leukemia. sion level of a gene selected from the genes shown in Tables 0006. Accordingly, in one embodiment the invention pro 6A, 6B, 6C, 6D, 7A, 7B, 7C, 7D, 8A, 8B, 8C, 8D,9A,9B, 9C, vides a method of diagnosing drug resistant leukemia in a 9D, 10A, 10B, 11A, 11B, 12A, 12B, 13A, and 13B, providing subject affected by leukemia. The method comprises the steps a cell that is resistant to an antileukemic agent; contacting the of providing a Subject expression profile of a sample from a cell with one or more compounds from the library of com Subject affected by leukemia, providing a reference expres pounds; creating a test expression profile by determining a sion profile associated with resistance to at least one antileu value representing the expression level in the cell of one or kemic agent selected from prednisolone, Vincristine, L-as more of the genes whose expression level is represented in the paraginase, and daunorubicin, and determining whether the reference expression profile, and determining whether the test subject expression profile shares sufficient similarity to the expression profile is distinguishable the reference expression reference expression profile, where the Subject is diagnosed profile.
Recommended publications
  • Reprogramming of Trna Modifications Controls the Oxidative Stress Response by Codon-Biased Translation of Proteins

    Reprogramming of Trna Modifications Controls the Oxidative Stress Response by Codon-Biased Translation of Proteins

    Reprogramming of tRNA modifications controls the oxidative stress response by codon-biased translation of proteins The MIT Faculty has made this article openly available. Please share how this access benefits you. Your story matters. Citation Chan, Clement T.Y. et al. “Reprogramming of tRNA Modifications Controls the Oxidative Stress Response by Codon-biased Translation of Proteins.” Nature Communications 3 (2012): 937. As Published http://dx.doi.org/10.1038/ncomms1938 Publisher Nature Publishing Group Version Author's final manuscript Citable link http://hdl.handle.net/1721.1/76775 Terms of Use Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use. Reprogramming of tRNA modifications controls the oxidative stress response by codon-biased translation of proteins Clement T.Y. Chan,1,2 Yan Ling Joy Pang,1 Wenjun Deng,1 I. Ramesh Babu,1 Madhu Dyavaiah,3 Thomas J. Begley3 and Peter C. Dedon1,4* 1Department of Biological Engineering, 2Department of Chemistry and 4Center for Environmental Health Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139; 3College of Nanoscale Science and Engineering, University at Albany, SUNY, Albany, NY 12203 * Corresponding author: PCD, Department of Biological Engineering, NE47-277, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA 02139; tel 617-253-8017; fax 617-324-7554; email [email protected] 2 ABSTRACT Selective translation of survival proteins is an important facet of cellular stress response. We recently demonstrated that this translational control involves a stress-specific reprogramming of modified ribonucleosides in tRNA.
  • Allele-Specific Expression of Ribosomal Protein Genes in Interspecific Hybrid Catfish

    Allele-Specific Expression of Ribosomal Protein Genes in Interspecific Hybrid Catfish

    Allele-specific Expression of Ribosomal Protein Genes in Interspecific Hybrid Catfish by Ailu Chen A dissertation submitted to the Graduate Faculty of Auburn University in partial fulfillment of the requirements for the Degree of Doctor of Philosophy Auburn, Alabama August 1, 2015 Keywords: catfish, interspecific hybrids, allele-specific expression, ribosomal protein Copyright 2015 by Ailu Chen Approved by Zhanjiang Liu, Chair, Professor, School of Fisheries, Aquaculture and Aquatic Sciences Nannan Liu, Professor, Entomology and Plant Pathology Eric Peatman, Associate Professor, School of Fisheries, Aquaculture and Aquatic Sciences Aaron M. Rashotte, Associate Professor, Biological Sciences Abstract Interspecific hybridization results in a vast reservoir of allelic variations, which may potentially contribute to phenotypical enhancement in the hybrids. Whether the allelic variations are related to the downstream phenotypic differences of interspecific hybrid is still an open question. The recently developed genome-wide allele-specific approaches that harness high- throughput sequencing technology allow direct quantification of allelic variations and gene expression patterns. In this work, I investigated allele-specific expression (ASE) pattern using RNA-Seq datasets generated from interspecific catfish hybrids. The objective of the study is to determine the ASE genes and pathways in which they are involved. Specifically, my study investigated ASE-SNPs, ASE-genes, parent-of-origins of ASE allele and how ASE would possibly contribute to heterosis. My data showed that ASE was operating in the interspecific catfish system. Of the 66,251 and 177,841 SNPs identified from the datasets of the liver and gill, 5,420 (8.2%) and 13,390 (7.5%) SNPs were identified as significant ASE-SNPs, respectively.
  • Predicting Clinical Response to Treatment with a Soluble Tnf-Antagonist Or Tnf, Or a Tnf Receptor Agonist

    Predicting Clinical Response to Treatment with a Soluble Tnf-Antagonist Or Tnf, Or a Tnf Receptor Agonist

    (19) TZZ _ __T (11) EP 2 192 197 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 02.06.2010 Bulletin 2010/22 C12Q 1/68 (2006.01) (21) Application number: 08170119.5 (22) Date of filing: 27.11.2008 (84) Designated Contracting States: (72) Inventor: The designation of the inventor has not AT BE BG CH CY CZ DE DK EE ES FI FR GB GR yet been filed HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR (74) Representative: Habets, Winand Designated Extension States: Life Science Patents AL BA MK RS PO Box 5096 6130 PB Sittard (NL) (71) Applicant: Vereniging voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek en Patiëntenzorg 1081 HV Amsterdam (NL) (54) Predicting clinical response to treatment with a soluble tnf-antagonist or tnf, or a tnf receptor agonist (57) The invention relates to methods for predicting a clinical response to a therapy with a soluble TNF antagonist, TNF or a TNF receptor agonist and a kit for use in said methods. EP 2 192 197 A1 Printed by Jouve, 75001 PARIS (FR) EP 2 192 197 A1 Description [0001] The invention relates to methods for predicting a clinical response to a treatment with a soluble TNF antagonist, with TNF or a TNF receptor agonist using expression levels of genes of the Type I INF pathway and a kit for use in said 5 methods. In another aspect, the invention relates to a method for evaluating a pharmacological effect of a treatment with a soluble TNF antagonist, TNF or a TNF receptor agonist.
  • Association of Gene Ontology Categories with Decay Rate for Hepg2 Experiments These Tables Show Details for All Gene Ontology Categories

    Association of Gene Ontology Categories with Decay Rate for Hepg2 Experiments These Tables Show Details for All Gene Ontology Categories

    Supplementary Table 1: Association of Gene Ontology Categories with Decay Rate for HepG2 Experiments These tables show details for all Gene Ontology categories. Inferences for manual classification scheme shown at the bottom. Those categories used in Figure 1A are highlighted in bold. Standard Deviations are shown in parentheses. P-values less than 1E-20 are indicated with a "0". Rate r (hour^-1) Half-life < 2hr. Decay % GO Number Category Name Probe Sets Group Non-Group Distribution p-value In-Group Non-Group Representation p-value GO:0006350 transcription 1523 0.221 (0.009) 0.127 (0.002) FASTER 0 13.1 (0.4) 4.5 (0.1) OVER 0 GO:0006351 transcription, DNA-dependent 1498 0.220 (0.009) 0.127 (0.002) FASTER 0 13.0 (0.4) 4.5 (0.1) OVER 0 GO:0006355 regulation of transcription, DNA-dependent 1163 0.230 (0.011) 0.128 (0.002) FASTER 5.00E-21 14.2 (0.5) 4.6 (0.1) OVER 0 GO:0006366 transcription from Pol II promoter 845 0.225 (0.012) 0.130 (0.002) FASTER 1.88E-14 13.0 (0.5) 4.8 (0.1) OVER 0 GO:0006139 nucleobase, nucleoside, nucleotide and nucleic acid metabolism3004 0.173 (0.006) 0.127 (0.002) FASTER 1.28E-12 8.4 (0.2) 4.5 (0.1) OVER 0 GO:0006357 regulation of transcription from Pol II promoter 487 0.231 (0.016) 0.132 (0.002) FASTER 6.05E-10 13.5 (0.6) 4.9 (0.1) OVER 0 GO:0008283 cell proliferation 625 0.189 (0.014) 0.132 (0.002) FASTER 1.95E-05 10.1 (0.6) 5.0 (0.1) OVER 1.50E-20 GO:0006513 monoubiquitination 36 0.305 (0.049) 0.134 (0.002) FASTER 2.69E-04 25.4 (4.4) 5.1 (0.1) OVER 2.04E-06 GO:0007050 cell cycle arrest 57 0.311 (0.054) 0.133 (0.002)
  • MIRA-Assisted Microarray Analysis, a New Technology for The

    MIRA-Assisted Microarray Analysis, a New Technology for The

    Research Article MIRA-Assisted Microarray Analysis, a New Technology for the Determination of DNA Methylation Patterns, Identifies Frequent Methylation of Homeodomain-Containing Genes in Lung Cancer Cells Tibor Rauch,1 Hongwei Li,1 Xiwei Wu,2 and Gerd P. Pfeifer1 Divisions of 1Biology and 2Biomedical Informatics, Beckman Research Institute of the City of Hope, Duarte, California Abstract hypermethylation generally leads to inactivation of gene expres- We present a straightforward and comprehensive approach sion, this epigenetic alteration is considered to be a key mechanism for DNA methylation analysis in mammalian genomes. The for long-term silencing of tumor suppressor genes. The importance methylated-CpG island recovery assay (MIRA), which is based of promoter methylation in functional inactivation of lung cancer on the high affinity of the MBD2/MBD3L1 complex for suppressor genes is becoming increasingly recognized. It is methylated DNA, has been used to detect cell type–dependent estimated that between 0.5% and 3% of all genes carrying CpG- differences in DNA methylation on a microarray platform. The rich promoter sequences (so-called CpG islands) may be silenced procedure has been verified and applied to identify a series of by DNA methylation in lung cancer (1, 11). This means that there novel candidate lung tumor suppressor genes and potential are most likely several hundred genes that are incapacitated by this DNA methylation markers that contain methylated CpG pathway. Some of these genes may be bona fide tumor suppressor islands. One gene of particular interest was DLEC1, located genes, but in other cases, the methylation event may be a at a commonly deleted area on chromosome 3p22-p21.3, consequence of gene silencing or may somehow be associated with which was frequently methylated in primary lung cancers and tumor formation rather than being a cause of tumorigenesis.
  • The VE-Cadherin/Amotl2 Mechanosensory Pathway Suppresses Aortic In�Ammation and the Formation of Abdominal Aortic Aneurysms

    The VE-Cadherin/Amotl2 Mechanosensory Pathway Suppresses Aortic InAmmation and the Formation of Abdominal Aortic Aneurysms

    The VE-cadherin/AmotL2 mechanosensory pathway suppresses aortic inammation and the formation of abdominal aortic aneurysms Yuanyuan Zhang Karolinska Institute Evelyn Hutterer Karolinska Institute Sara Hultin Karolinska Institute Otto Bergman Karolinska Institute Maria Forteza Karolinska Institute Zorana Andonovic Karolinska Institute Daniel Ketelhuth Karolinska University Hospital, Stockholm, Sweden Joy Roy Karolinska Institute Per Eriksson Karolinska Institute Lars Holmgren ( [email protected] ) Karolinska Institute Article Keywords: arterial endothelial cells (ECs), vascular disease, abdominal aortic aneurysms Posted Date: June 15th, 2021 DOI: https://doi.org/10.21203/rs.3.rs-600069/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License The VE-cadherin/AmotL2 mechanosensory pathway suppresses aortic inflammation and the formation of abdominal aortic aneurysms Yuanyuan Zhang1, Evelyn Hutterer1, Sara Hultin1, Otto Bergman2, Maria J. Forteza2, Zorana Andonovic1, Daniel F.J. Ketelhuth2,3, Joy Roy4, Per Eriksson2 and Lars Holmgren1*. 1Department of Oncology-Pathology, BioClinicum, Karolinska Institutet, Stockholm, Sweden. 2Department of Medicine Solna, BioClinicum, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden. 3Department of Cardiovascular and Renal Research, Institutet of Molecular Medicine, Univ. of Southern Denmark, Odense, Denmark 4Department of Molecular Medicine and Surgery, Karolinska Institutet, Karolinska University Hospital, Stockholm,
  • Inflammation Leads to Distinct Populations of Extracellular Vesicles from Microglia Yiyi Yang1* , Antonio Boza-Serrano1, Christopher J

    Inflammation Leads to Distinct Populations of Extracellular Vesicles from Microglia Yiyi Yang1* , Antonio Boza-Serrano1, Christopher J

    Yang et al. Journal of Neuroinflammation (2018) 15:168 https://doi.org/10.1186/s12974-018-1204-7 RESEARCH Open Access Inflammation leads to distinct populations of extracellular vesicles from microglia Yiyi Yang1* , Antonio Boza-Serrano1, Christopher J. R. Dunning2, Bettina Hjelm Clausen3,4, Kate Lykke Lambertsen3,4,5 and Tomas Deierborg1* Abstract Background: Activated microglia play an essential role in inflammatory responses elicited in the central nervous system (CNS). Microglia-derived extracellular vesicles (EVs) are suggested to be involved in propagation of inflammatory signals and in the modulation of cell-to-cell communication. However, there is a lack of knowledge on the regulation of EVs and how this in turn facilitates the communication between cells in the brain. Here, we characterized microglial EVs under inflammatory conditions and investigated the effects of inflammation on the EV size, quantity, and protein content. Methods: We have utilized western blot, nanoparticle tracking analysis (NTA), and mass spectrometry to characterize EVs and examine the alterations of secreted EVs from a microglial cell line (BV2) following lipopolysaccharide (LPS) and tumor necrosis factor (TNF) inhibitor (etanercept) treatments, or either alone. The inflammatory responses were measured with multiplex cytokine ELISA and western blot. We also subjected TNF knockout mice to experimental stroke (permanent middle cerebral artery occlusion) and validated the effect of TNF inhibition on EV release. Results: Our analysis of EVs originating from activated BV2 microglia revealed a significant increase in the intravesicular levels of TNF and interleukin (IL)-6. We also observed that the number of EVs released was reduced both in vitro and in vivo when inflammation was inhibited via the TNF pathway.
  • Ribosomal Protein L3 Polyclonal Antibody Product Information

    Ribosomal Protein L3 Polyclonal Antibody Product Information

    Ribosomal Protein L3 Polyclonal Antibody Cat #: ABP52364 Size: 30μl /100μl /200μl Product Information Product Name: Ribosomal Protein L3 Polyclonal Antibody Applications: WB, IHC-P, ELISA Isotype: Rabbit IgG Reactivity: Human, Mouse, Rat Catalog Number: ABP52364 Lot Number: Refer to product label Formulation: Liquid Concentration: 1 mg/ml Storage: Store at -20°C. Avoid repeated Note: Contain sodium azide. freeze / thaw cycles. Background: Ribosomes, the complexes that catalyze protein synthesis, consist of a small 40S subunit and a large 60S subunit. Together these subunits are composed of 4 RNA species and approximately 80 structurally distinct proteins. This gene encodes a ribosomal protein that is a component of the 60S subunit. 60S ribosomal protein L3 belongs to the L3P family of ribosomal proteins and it is located in the cytoplasm. The protein can bind to the HIV-1 TAR mRNA, and it has been suggested that the protein contributes to tat-mediated transactivation. This gene is co-transcribed with several small nucleolar RNA genes, which are located in several of this gene's introns. Alternate transcriptional splice variants, encoding different isoforms, have been characterized. As is typical for genes encoding ribosomal proteins, there are multiple processed pseudogenes of this gene dispersed through the genome. Application Notes: Optimal working dilutions should be determined experimentally by the investigator. Suggested starting dilutions are as follows: WB (1:500-1:2000), IHC-P (1:100-1:300), ELISA (1:20000). Not yet tested in other applications. Storage Buffer: PBS containing 50% Glycerol, 0.5% BSA and 0.02% Sodium Azide. Storage Instructions: Stable for one year at -20°C from date of shipment.
  • Supplementary Table 1. the List of Proteins with at Least 2 Unique

    Supplementary Table 1. the List of Proteins with at Least 2 Unique

    Supplementary table 1. The list of proteins with at least 2 unique peptides identified in 3D cultured keratinocytes exposed to UVA (30 J/cm2) or UVB irradiation (60 mJ/cm2) and treated with treated with rutin [25 µM] or/and ascorbic acid [100 µM]. Nr Accession Description 1 A0A024QZN4 Vinculin 2 A0A024QZN9 Voltage-dependent anion channel 2 3 A0A024QZV0 HCG1811539 4 A0A024QZX3 Serpin peptidase inhibitor 5 A0A024QZZ7 Histone H2B 6 A0A024R1A3 Ubiquitin-activating enzyme E1 7 A0A024R1K7 Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein 8 A0A024R280 Phosphoserine aminotransferase 1 9 A0A024R2Q4 Ribosomal protein L15 10 A0A024R321 Filamin B 11 A0A024R382 CNDP dipeptidase 2 12 A0A024R3V9 HCG37498 13 A0A024R3X7 Heat shock 10kDa protein 1 (Chaperonin 10) 14 A0A024R408 Actin related protein 2/3 complex, subunit 2, 15 A0A024R4U3 Tubulin tyrosine ligase-like family 16 A0A024R592 Glucosidase 17 A0A024R5Z8 RAB11A, member RAS oncogene family 18 A0A024R652 Methylenetetrahydrofolate dehydrogenase 19 A0A024R6C9 Dihydrolipoamide S-succinyltransferase 20 A0A024R6D4 Enhancer of rudimentary homolog 21 A0A024R7F7 Transportin 2 22 A0A024R7T3 Heterogeneous nuclear ribonucleoprotein F 23 A0A024R814 Ribosomal protein L7 24 A0A024R872 Chromosome 9 open reading frame 88 25 A0A024R895 SET translocation 26 A0A024R8W0 DEAD (Asp-Glu-Ala-Asp) box polypeptide 48 27 A0A024R9E2 Poly(A) binding protein, cytoplasmic 1 28 A0A024RA28 Heterogeneous nuclear ribonucleoprotein A2/B1 29 A0A024RA52 Proteasome subunit alpha 30 A0A024RAE4 Cell division cycle 42 31
  • Inhibition of the MID1 Protein Complex

    Inhibition of the MID1 Protein Complex

    Matthes et al. Cell Death Discovery (2018) 4:4 DOI 10.1038/s41420-017-0003-8 Cell Death Discovery ARTICLE Open Access Inhibition of the MID1 protein complex: a novel approach targeting APP protein synthesis Frank Matthes1,MoritzM.Hettich1, Judith Schilling1, Diana Flores-Dominguez1, Nelli Blank1, Thomas Wiglenda2, Alexander Buntru2,HannaWolf1, Stephanie Weber1,InaVorberg 1, Alina Dagane2, Gunnar Dittmar2,3,ErichWanker2, Dan Ehninger1 and Sybille Krauss1 Abstract Alzheimer’s disease (AD) is characterized by two neuropathological hallmarks: senile plaques, which are composed of amyloid-β (Aβ) peptides, and neurofibrillary tangles, which are composed of hyperphosphorylated tau protein. Aβ peptides are derived from sequential proteolytic cleavage of the amyloid precursor protein (APP). In this study, we identified a so far unknown mode of regulation of APP protein synthesis involving the MID1 protein complex: MID1 binds to and regulates the translation of APP mRNA. The underlying mode of action of MID1 involves the mTOR pathway. Thus, inhibition of the MID1 complex reduces the APP protein level in cultures of primary neurons. Based on this, we used one compound that we discovered previously to interfere with the MID1 complex, metformin, for in vivo experiments. Indeed, long-term treatment with metformin decreased APP protein expression levels and consequently Aβ in an AD mouse model. Importantly, we have initiated the metformin treatment late in life, at a time-point where mice were in an already progressed state of the disease, and could observe an improved behavioral phenotype. These 1234567890 1234567890 findings together with our previous observation, showing that inhibition of the MID1 complex by metformin also decreases tau phosphorylation, make the MID1 complex a particularly interesting drug target for treating AD.
  • PNAS 07-04849-SI Table 3. 6-18-2007

    PNAS 07-04849-SI Table 3. 6-18-2007

    Table 5. β-arrestin 2-interacting proteins under nonstimulated (-) condition IPI accession Swiss- Number of Prot Gene symbol Protein name experiments accession number number detected Signal transduction Adaptor proteins IPI00027355 P32121 ARRB2 β-arrestin 2 6 IPI00293857 P49407 ARRB1 β-arrestin 1 6 IPI00021353 P10523 SAG S-arrestin (Retinal S-antigen) (48 kDa protein) (S-AG) (Rod photoreceptor arrestin) 2 IPI00003917 P36575 ARR3 X-arrestin (Arrestin-C) (Cone arrestin) (cArr) (Retinal cone arrestin-3) (C-arrestin) 2 IPI00216318 P31946 YWHAB 14-3-3 β/α (14-3-3 protein beta/alpha) (Protein kinase C inhibitor protein 1) (KCIP-1) (Protein 1054) 2 IPI00220642 P61981 YWHAG 14-3-3 γ (14-3-3 protein gamma) (Protein kinase C inhibitor protein 1) (KCIP-1) 2 IPI00018146 P27348 YWHAQ 14-3-3 θ (14-3-3 protein tau) (14-3-3 protein theta) (14-3-3 protein T-cell) (HS1 protein) 2 IPI00216319 Q04917 YWHAH 14-3-3 η (14-3-3 protein eta) (Protein AS1) 2 IPI00000816 P62258 YWHAE 14-3-3 ε (14-3-3 protein epsilon) (14-3-3E) 2 Protein kinases IPI00027251 Q15208 STK38 STK38 (Serine/threonine-protein kinase 38) (NDR1 protein kinase) (Nuclear Dbf2-related kinase 1) 4 SCY1-like 2 (SCY1-like 2 protein) (coated vesicle-associated kinase of 104 kDa) (Eukaryotic protein IPI00396218 Q6P3W7 SCYL2 2 kinase family protein) (CDNA FLJ10074 fis, clone HEMBA1001744, weakly similar to SCY1 IPI00013835 Q13574 DGKZ DGK ζ (Diacylglycerol kinase zeta) (Diglyceride kinase zeta) (DGK-zeta) (DAG kinase zeta) 2 DGK ε (Diacylglycerol kinase epsilon) (Diglyceride kinase epsilon) (DGK-epsilon)
  • (HBV) Infection of the Liver Ahmed Mohamed Abdel-B Diab Purdue University

    (HBV) Infection of the Liver Ahmed Mohamed Abdel-B Diab Purdue University

    Purdue University Purdue e-Pubs Open Access Dissertations Theses and Dissertations January 2016 The oler of PLK1 in Hepatitis B Virus (HBV) infection of the liver Ahmed Mohamed Abdel-B Diab Purdue University Follow this and additional works at: https://docs.lib.purdue.edu/open_access_dissertations Recommended Citation Diab, Ahmed Mohamed Abdel-B, "The or le of PLK1 in Hepatitis B Virus (HBV) infection of the liver" (2016). Open Access Dissertations. 1214. https://docs.lib.purdue.edu/open_access_dissertations/1214 This document has been made available through Purdue e-Pubs, a service of the Purdue University Libraries. Please contact [email protected] for additional information. Graduate School Form 30 Updated 12/26/2015 PURDUE UNIVERSITY GRADUATE SCHOOL Thesis/Dissertation Acceptance This is to certify that the thesis/dissertation prepared By Ahmed Mohamed Abdel-B Diab Entitled The role of PLK1 in Hepatitis B Virus (HBV) Infection of the Liver For the degree of Doctor of Philosophy Is approved by the final examining committee: Ourania Andrisani Andy W. Tao Co-chair Fabien Zoulim Co-chair Robert Geahlen Xiaoqi Liu To the best of my knowledge and as understood by the student in the Thesis/Dissertation Agreement, Publication Delay, and Certification Disclaimer (Graduate School Form 32), this thesis/dissertation adheres to the provisions of Purdue University’s “Policy of Integrity in Research” and the use of copyright material. Approved by Major Professor(s): Ourania Andrisani Laurie Jaeger 10/6/2016 Approved by: Head of the Departmental Graduate Program Date i THE ROLE OF PLK1 IN HEPATITIS B VIRUS (HBV) INFECTION OF THE LIVER A Dissertation Submitted to the Faculty of Purdue University by Ahmed M Diab In Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy December 2016 Purdue University West Lafayette, Indiana ii ACKNOWLEDGEMENTS I would like to begin by extending my gratitude to my committee members Robert Geahlen, Andy W.